Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus

Drugs

Volumn 75, Issue 10, 2015, Pages 1141-1152

  Syed, Yahiya Y ^a   McCormack, Paul L ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SITAGLIPTIN; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; PEPTIDE; VENOM;

ARTHRALGIA; ARTICLE; BACKACHE; CARDIOMETABOLIC RISK; CONSTIPATION; COUGHING; DIARRHEA; DIET; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EXERCISE; GALLBLADDER DISEASE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE NODULE; INJECTION SITE PRURITUS; KIDNEY FAILURE; MALAISE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL PAIN; NATURAL SCIENCE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT SATISFACTION; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; RISK FACTOR; SINUSITIS; SUBCUTANEOUS NODULE; THYROID TUMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ADVERSE EFFECTS; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; PHARMACOKINETICS; PHARMACOLOGY; THERAPEUTIC USE;

DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT SATISFACTION; PEPTIDES; QUALITY OF LIFE; VENOMS;

EID: 84937732919     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0420-z     Document Type: Article

References (53)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-9.
2. American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care. 2014;37(Suppl 1):S14-80.
3. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm. Endocr Pract. 2013;19(2):327-36.
4. Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122(6 Suppl):S3-10.
5. McCormack PL. Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. Drugs. 2014;74(3):325-51.
6. DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145-54.
7. ® (exenatide extended-release for injectable suspension): US prescribing information. 2012. http://www.accessdata.fda.gov. Accessed 27 May 2015.
8. LaRue S, Malloy J, Halili RB. Dual-chamber pen design and testing for injection of exenatide dispersed in poly-(D,L-lactide-co-glycolide) microspheres for once-weekly treatment of type 2 diabetes [abstract no. P-257]. In: 7th International Conference on Advanced Technology & Treatments for Diabetes. 2014.
9. European Medicines Agency. Bydureon 2 mg powder and solvent for prolonged-release suspension for injection: summary of product characteristics. 2011. http://www.ema.europa.eu. Accessed 27 May 2015.
10. ® Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes [media release]. 3 March 2014. http://www.astrazeneca.com.
11. Scott LJ. Exenatide extended-release: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(12):1679-707.
12. Cvetkovic RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs. 2007;67(6):935-54.
13. Kim DM, Macconell LP, Zhuang DP, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487-93.
14. Iwamoto K, Nasu R, Yamamura A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J. 2009;56(8):951-62.
15. Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4(1):53-61.
16. Inagaki N, Atsumi Y, Oura T, et al. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther. 2012;34(9):1892-908.
17. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252-8.
18. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234-43.
19. Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care. 2012;35(4):683-9.
20. Darpö B, Philip S, MacConell L, et al. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol. 2013;75(4):979-89.
21. Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011;50(1):65-74.
22. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-50.
23. Cui YM, Guo XH, Zhang DM, et al. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus. J Diabetes. 2013;5(2):127-35.
24. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301-10.
25. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-24.
26. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431-9.
27. Davies M, Heller S, Sreenan S, et al. Once-weekly exenatide versus once- or twice-daily insulin detemir. Diabetes Care. 2013;36(5):1368-76.
28. Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2(6):464-73.
29. Macconell L, Pencek R, Li Y, et al. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31-41.
30. Henry RR, Klein EJ, Malloy J, et al. DURATION-1 extension: efficacy and tolerability of exenatide once weekly (QW) over 6 years in patients with T2DM [abstract no. 964-P]. In: 74th Annual Scientific Sessions of the American Diabetes Association. 2014.
31. Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33(6):1255-61.
32. Taylor K, Gurney K, Han J, et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord. 2011;11:9.
33. Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011;28(6):705-14.
34. Wysham CH, MacConell LA, Maggs DG, et al. Five-year efficacy and safety data of exenatide once weekly: long-term results from the randomized, controlled DURATION-1 trial. Mayo Clin Proc. 2015;90(3):356-65.
35. Scott DA, Boye KS, Timlin L, et al. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab. 2013;15(3):213-23.
36. Grimm M, Li Y, Brunell SC, et al. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control. Postgrad Med. 2013;125(5):101-8.
37. Malloy J, Meloni A, Han J. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data. Postgrad Med. 2013;125(3):58-67.
38. Grimm M, Han J, Weaver C, et al. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. Postgrad Med. 2013;125(3):47-57.
39. Norwood P, Liutkus JF, Haber H, et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther. 2012;34(10):2082-90.
40. Blonde L, Macconell L, Huang W, et al. Exenatide once weekly: association between weight response, glycemic control, and markers of cardiovascular risk [abstract no. 1182-P]. Diabetes. 2013;62(Suppl 1):A308-9.
41. Chilton RJ, MacConell LA, Han JC, et al. Characterization of heart rate increases with glucagon-like peptide-1 agonist therapy [abstract no. A16290]. Circulation. 2013;128(Suppl 2).
42. Best JH, Boye KS, Rubin RR, et al. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med. 2009;26(7):722-8.
43. Best JH, Rubin RR, Peyrot M, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care. 2011;34(2):314-9.
44. MacConell L, Gurney K, Malloy J, et al. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes. 2015;8:241-53.
45. Ridge T, Moretto T, MacConell L, et al. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(12):1097-103.
46. Cirincione B, Edwards J, Aisporna M, et al. Gastrointestinal tolerability with twice-daily or once-weekly exenatide formulations was not predicted by concentration with long-term treatment [abstract no. 910]. Diabetologia. 2013;56(Suppl 1):S363.
47. Tuttle KR, Heilmann C, Hoogwerf BJ, et al. Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes. Am J Kidney Dis. 2013;62(2):396-8.
48. Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012;14(6):546-54.
49. Gaebler JA, Soto-Campos G, Alperin P, et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag. 2012;8(1):255-64.
50. Guillermin AL, Lloyd A, Best JH, et al. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. J Med Econ. 2012;15(4):654-63.
51. Samyshkin Y, Guillermin AL, Best JH, et al. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J Med Econ. 2012;15(Suppl 2):6-13.
52. 2 in Spain. J Med Econ. 2013;16(7):926-38.
53. Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119-33.